Literature DB >> 3301303

Management of cardiac arrhythmias during pregnancy. Current concepts.

H H Rotmensch, S Rotmensch, U Elkayam.   

Abstract

Cardiac arrhythmia is one of the most common reasons for cardiac consultation during pregnancy. Fortunately, malignant arrhythmias during the course of normal gestation are rare, and the relatively common complaint of palpitations is usually due to benign arrhythmias. However, in pregnant patients with organic heart disease, arrhythmias are often triggered by the haemodynamic burden of pregnancy and may be the first manifestation of the disease. In addition, rhythm abnormalities in patients with limited cardiac reserves may have significant haemodynamic consequences and can compromise fetal well-being. Any woman who presents with rhythm disorders during pregnancy should undergo a diagnostic evaluation to rule out an underlying disease, including cardiac, pulmonary, endocrine, or metabolic disease. Additionally, removal of precipitating factors, such as excessive ingestion of caffeine and/or alcohol, cigarette smoking, drug abuse or therapy with arrhythmogenic compounds, is indicated (as these measures are desirable in any pregnant woman). Antiarrhythmic drug therapy is indicated in such patients only in symptomatic or haemodynamically significant arrhythmias. In cases where organic heart disease or any other cause for arrhythmia is identified, the underlying disease should be treated first. Antiarrhythmic drug therapy is indicated when arrhythmias persist or as a prophylactic measure. In principle, the approach to drug therapy in pregnant patients is similar to that in non-pregnant patients. However, special consideration should be given to drug selection in order to avoid adverse effects to the fetus. Those antiarrhythmics that have been shown to be relatively safe during pregnancy include digoxin, quinidine, procainamide, some beta-blocking drugs and lignocaine (lidocaine). In addition to careful drug selection, the smallest effective dose should be used and the indication for antiarrhythmic therapy should be periodically reassessed during the course of pregnancy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3301303     DOI: 10.2165/00003495-198733060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  62 in total

1.  DIRECT-CURRENT DEFIBRILLATION DURING PREGNANCY.

Authors:  J H VOGEL; R PRYOR; S G BLOUNT
Journal:  JAMA       Date:  1965-09-13       Impact factor: 56.272

2.  Placental and milk transfer of disopyramide and metabolites.

Authors:  A Karim; C Kook; J Campion
Journal:  Drug Metab Dispos       Date:  1978 May-Jun       Impact factor: 3.922

3.  Excretion of drugs in human milk.

Authors:  M Levy; L Granit; N Laufer
Journal:  N Engl J Med       Date:  1977-10-06       Impact factor: 91.245

4.  Effects on the neonate of propranolol administered during pregnancy.

Authors:  A Habib; J S McCarthy
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

5.  Placental transfer of lidocaine: effects of fetal acidosis.

Authors:  D Biehl; S M Shnider; G Levinson; K Callender
Journal:  Anesthesiology       Date:  1978-06       Impact factor: 7.892

6.  Refractory supraventricular tachycardia complicating pregnancy.

Authors:  G J Robards; D M Saunders; G L Donnelly
Journal:  Med J Aust       Date:  1973-08-11       Impact factor: 7.738

7.  Amiodarone in pregnancy.

Authors:  I M Penn; P A Barrett; V Pannikote; P F Barnaby; J B Campbell; N R Lyons
Journal:  Am J Cardiol       Date:  1985-07-01       Impact factor: 2.778

8.  Association of hemorrhagic disease and the syndrome of persistent fetal circulation with the fetal hydantoin syndrome.

Authors:  W E Truog; J H Feusner; D L Baker
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

9.  Transplacental cardioversion of fetal supraventricular tachycardia with procainamide.

Authors:  D A Dumesic; N H Silverman; S Tobias; M S Golbus
Journal:  N Engl J Med       Date:  1982-10-28       Impact factor: 91.245

10.  Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate.

Authors:  R W Allen; B Ogden; F L Bentley; A L Jung
Journal:  JAMA       Date:  1980-09-26       Impact factor: 56.272

View more
  5 in total

Review 1.  Drug treatment of fetal tachycardias.

Authors:  Martijn A Oudijk; Jopje M Ruskamp; Barbara E Ambachtsheer; Tessa F F Ververs; Philip Stoutenbeek; Gerard H A Visser; Erik J Meijboom
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 2.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Electrical cardioversion.

Authors:  Murat Sucu; Vedat Davutoglu; Orhan Ozer
Journal:  Ann Saudi Med       Date:  2009 May-Jun       Impact factor: 1.526

4.  Incidence and Time Course of Symptomatic Paroxysmal Supraventricular Tachycardia During Pregnancy: A Nation-Wide Database Study.

Authors:  Kuang-Tso Lee; Shang-Hung Chang; Chang-Fu Kuo; Meng-Jiun Chiou; Ming-Shien Wen
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

5.  Emergency cesarean delivery in a parturient who had an intractable paroxysmal supraventricular tachycardia -A case report-.

Authors:  Kyoung Ok Kim; Eun-Jung Chang; Jin Han; Hun Cho
Journal:  Korean J Anesthesiol       Date:  2012-10-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.